PATENT CLAIM ANALYSIS

Application Number: 15866773
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "133100"]

Abstract:
The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Claim (Index 39):
The humanized antibody according to  claim 1 , wherein said humanized antibody specifically binds to a pyroglutamate carrying N-terminus of the A\u03b2 N3pE epitope.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.875
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14844726', '12500940', '13252929', '14280919', '13422583']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7997261186987774
- 35 USC 102 Novelty (BERT): 0.5897215972591786
- Combined Prediction Score: 0.7787256665548176
- Mean Citation Score: 512.6510959999998
- Max Citation Score: 518.76483
- Similarity Product: 415.1328014072012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test